Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx (Nasdaq: LUNG) announced that on December 1, 2025 it granted equity awards under its 2025 Inducement Plan totaling 1,625,000 shares to two executives hired in Q4 2025, including CFO Derrick Sung.
The awards comprise 1,225,000 RSUs (Mr. Sung received 1,200,000 RSUs) that vest 25% after one year and then quarterly over three years. Mr. Sung also received up to 400,000 PSUs subject to a time-based vesting schedule (33% at one year, then quarterly over two years) and a 60-trading-day average closing price performance condition. The Inducement Plan was adopted by the board in November 2025 and complies with Nasdaq Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported third quarter 2025 results for the period ended September 30, 2025: total revenue $21.5M (+5% vs Q3 2024; +4% constant currency), with U.S. revenue $14.0M (+1% YoY) and international revenue $7.5M (+15% YoY; +9% constant currency). Gross profit was $16.1M and gross margin 75%. Operating expenses were $30.4M and net loss was $14.0M ($0.34 per share). Adjusted EBITDA loss was $8.2M. Cash and cash equivalents totaled $76.5M at quarter end. Pulmonx updated full-year 2025 guidance to $89M–$90M revenue, ~73% gross margin, and $125M–$126M operating expenses (including ~$21M stock-based compensation).
Pulmonx (NASDAQ: LUNG) announced a management transition and preliminary third quarter 2025 revenue on October 27, 2025. Glen French is reappointed President and CEO effective immediately; Derrick Sung will become COO and CFO effective November 3, 2025. Two executives, Steve Williamson and Mehul Joshi, resigned and will serve as advisors through December 1, 2025. The company reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million. Third quarter 2025 financial results and a conference call were rescheduled for November 12, 2025 at 1:30 p.m. PT / 4:30 p.m. ET. The revenue figure is preliminary and subject to revision when full results are released.
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.
Pulmonx (NASDAQ:LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4 at 1:30 PM PT in Boston, with a webcast available. Additionally, management will attend the Lake Street Best Ideas Growth Conference on September 11 in New York for one-on-one meetings. Investors can access the Wells Fargo fireside chat webcast through Pulmonx's investor relations website.
Pulmonx (Nasdaq: LUNG) reported its Q2 2025 financial results, achieving total revenue of $23.9 million, representing a 15% year-over-year increase. The company's performance was driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).
The company maintained a gross margin of 72% but reported a net loss of $15.2 million ($0.38 per share). Due to slower-than-expected U.S. revenue conversion, Pulmonx revised its full-year 2025 guidance down to $90-92 million from the previous $96-98 million forecast. Operating expenses are now expected to be $128-130 million, reduced from prior guidance of $133-135 million.
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference. The presentation is scheduled for June 11, 2025, at 7:00 AM PT / 10:00 AM ET in Miami. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET in Las Vegas. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
